The Russian healthcare system received 1.66 million packages of botulinum toxin-based drugs in 2025. As GxP News was informed by the analytical company RNC Pharma, this is the highest figure in the last 10 years. The previous year, the supply volume amounted to 1.54 million packages. Thus, the increase reached 7.7%. In terms of equivalent active units, the market grew to 157 million units, which is 5.9% more than the result of 2024.
Despite the renewed record, the growth rate turned out to be one of the most restrained in the last seven years. Lower dynamics were observed only in 2023 (+0.7% in packages), when the market faced the cessation of official supplies of Botox from Allergan and Botulax from Hugel Inc.
The category showed the most rapid growth in 2019–2021, when the annual increase in supplies averaged 85%. Analysts also recorded a significant rise in 2022 and 2024 — by 41% and 38%, respectively.
The range of legally supplied botulinum toxins to Russia remained stable in 2025. However, starting from January 2026, according to analysts, shipments of the drug Lantox from Binnopharm Group began. It had previously been on the market until 2018 but did not hold a significant share. The drug is also notable for the fact that its production is fully localized in China.
The leader in the number of packages supplied in 2025 was Relatox from Natsimbio — 630,300 packages, or 37.9% of the market. In action units, first place was taken by Dysport from Ipsen (52.6 million action units, 33.5% of the market), slightly ahead of Relatox (51.9 million action units). At the same time, the dynamics of the drugs were multidirectional: the volume of Dysport decreased by 9%, while Relatox increased by 13%.
The highest growth rate was demonstrated by Xeomin from Merz Pharma (+68% in action units), while Miotox from Innopharm and Novacutan-BTA from the Fizhi Institute of Beauty showed declines of 22% and 35%, respectively.
As GxP News reported earlier, the Russian botulinum toxin market is showing mixed dynamics. In cosmetology, domestic drugs Miotox and Relatox are gaining popularity. In the public sector, the situation is different: foreign brands lead here. At the same time, in 2025, government procurement of BTA drugs decreased slightly — for the first time in five years. Against this background, retail shows steady growth: over the year, sales volume reached 10.2 billion rubles, which was a three-year high.